Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alto Neuroscience, Inc. ( (ANRO) ) has shared an announcement.
On May 12, 2026, Alto Neuroscience, Inc. held its Annual Meeting, at which stockholders elected Class II directors Raymond Sanchez, M.D., and Gwill York to serve until the 2029 annual meeting, and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholders rejected an amendment to the 2024 Equity Incentive Plan that would have treated pre-funded warrants like common stock for the plan’s evergreen share calculations, but approved a similar amendment to the 2024 Employee Stock Purchase Plan, shaping how future share reserves are calculated for employee participation versus broader equity incentives and signaling nuanced investor views on dilution and capital structure.
The most recent analyst rating on (ANRO) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, large losses, and rising cash burn) despite a comparatively solid balance sheet. Technicals are supportive with strong upward trend and positive momentum, while valuation is pressured by ongoing unprofitability. Recent corporate events are mixed, with financing improving runway but clinical disappointment increasing program and execution risk.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates in the biopharmaceutical sector, focusing on neuroscience-driven therapies. The company develops treatments targeting mental health and neurological conditions, positioning itself within the broader life sciences market that emphasizes precision medicine and innovative brain health solutions.
Average Trading Volume: 301,848
Technical Sentiment Signal: Buy
Current Market Cap: $786.8M
Learn more about ANRO stock on TipRanks’ Stock Analysis page.